Proton magnetic resonance spectroscopy in alzheimer's disease, a review

Acta Neurologica Belgica

Volumn 110, Issue 4, 2010, Pages 291-298

  Loos, Caroline ^b   Achten, Eric ^a   Santens, Patrick ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Department of Neurology Ghent University Hospital ^*

Author keywords

Alzheimer disease; Brain metabolites; Dementia; Diagnosis; Differential diagnosis; Proton magnetic resonance spectroscopy

Indexed keywords

ALZHEIMER DISEASE; BRAIN FUNCTION; CLINICAL EVALUATION; COGNITION; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

EID: 79551646080     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000,355:1696-1697.
2. Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev. 1989;13:23-31.
3. 1 MRS in vivo. Magn Reson Med. 1999;41:193-197.
4. Brooks WM, Stidley CA, Petrpoulos H, Jung RE, Weers DC. et al. Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study. J Neurotrauma. 2000;17:629-640.
5. Dekosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S. et al. Upregulation of choline acetyl-transferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
6. Di Costanzo A, Trojsi F, Tosetti M, Schirmer T, Lechner SM, Popolizio T, Scarabino T. Proton MR spectroscopy of the brain at 3 T: an update. Eur Radiol. 2007;17:1651-1662.
7. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002;125:2332-2341.
8. Doraiswamy PM, Charles HC, Krishnan KR. Prediction of cognitive decline in early Alzheimer's disease. Lancet. 1998;352:1678.
9. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology. 1997;203:829-836.
10. Glanville NT, Byers DM, Cook HW, Spence MW, Palmer PB. Differences in the metabolism of inostitol and phophoinositides by cultured cells of neuronal and glial origin. Biochim Biophys Acta. 1989;1004:169-179.
11. Hartwig V, Giovannetti G, Vanello N, Lombardi M, Landini L, Simi S. Biological effects and safety in magnetic resonance imaging:a review. Int J Environ Res Public Health. 2009;6:1778-98.
12. Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS. et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology. 2001;57:626-632.
13. Jessen F, Block W, Träber F, Keller E, Flacke S. et al. Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology. 2000;55:684-688.
14. Jessen F, Block W, Traber F, Keller E, Flacke S. et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology. 2001;57:930-932. (Pubitemid 32845528)
15. Jessen F, Gür O, Block W, Ende G, Frölich L. et al. A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI. Neurology. 2009;72:1735-1740.
16. 1 MRS study. Neurology. 2000;55:210-217.
17. Kantarci K, Xu YC, Shiung MM, O'Brain PC, Cha RH. et al. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14:198-207.
18. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF. et al. 1H MR spectroscopy in common dementias. Neurology. 2004;63:1393-1398.
19. 1H Magnetic resonance spectroscopy in dementia. Br J Radiol. 2007;80:146-152.
20. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS. et al. Longitudinal (1)H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2007;28: 1330-1339.
21. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL. et al. Alzheimer disease:postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. Radiology. 2008;248:210-220.
22. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL. et al. Risk of dementia in MCI: Combined effect of cerebrovascular disease, volumetric MRI and 1H MRS. Neurology 2009;72: 1519-1525.
23. Kattapong VJ, Brooks WM, Wesley MH, Kodituwakku PW, Rosenberg GA. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch. Neurol. 1996;53:678-680.
24. Klunk WE, Panchalingam K, Moossy J, McClure RJ, Pettegrew JW. N-acetyl-L-aspartate and other amino acid metabolites in Alzheimer's disease brain: a preliminary proton nuclear magnetic resonance study. Neurology. 1992;42:1578-1585.
25. Knopman DS, Dekosky ST, Cummings JL, Chui H, Corey-Bloom J. et al. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
26. Kreis R, Ross BD, Farrow NA, Ackerman Z. Metabolic disorders of the brain in chronic hepatic encephalography detected with 1H MR spectroscopy. Radiology. 1992;182:19-27.
27. Kreis R, Ross BD. Cerebral metabolic disturbances in patients with subacute and chronic diabetes mellitus:detection with proton MR spectroscopy. Radiology. 1992;184:123-130.
28. Mackay S, Meyerhoff DJ, Constans JM, Norman D, Fein G. et al. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elerdy controls with 1H magnetic resonance spectrosopic imaging. Arch Neurol. 1996;53:167-174.
29. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D. et al. Rivastigmine in the treatment of dementia with Lewy bodies:preliminary findings from an open trail. Int J Geriatr Psychiatry. 2000;15:387-392.
30. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S. et al. Alzheimer disease:depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology. 1993;187:433-437. (Pubitemid 23127850)
31. Miller BL, Chang L, Booth R, Ernst T, Cornford M. et al. In vivo 1H MRS cholinexorrelation with in vitro chemistry/histology. Life Sci. 1996;58:1929-1935.
32. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med. 1994;32:110-115.
33. Modrego PJ, Pina MA, Fayed N, Diaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomized controlled trail with magnetic resonance spectroscopy. CNS Drugs. 2006;20:867-877.
34. Modrego PJ. The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. Curr Med Chem. 2006;13:3417-3424.
35. Pfefferbaum A, Adalsteinsson E, Spielman D, Sullivan EV, Lim KO. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease. Arch Gen Psychiatry. 1999;56: 185-192.
36. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK. et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology. 2002;44:371-381.
37. 1 spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites. NMR Biomed. 1991;4:59-63.
38. Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N. et al. In vivo MR spectroscopy of human dementia. Neuroimaging Clin N Am. 1998;8:809-822.
39. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatement with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry. 1997;154:1459-1461. (Pubitemid 27415619)
40. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J. et al. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology. 1997;49:1513-1521.
41. Schuff N, Amend DL, Meyerhoff DJ, Tanabe JL, Norman D. et al. Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain. Radiology. 1998;207:91-102. (Pubitemid 28168672)
42. Schuff N, Capizzano AA, Du AT, Amend DL, O'Neill J, Norman D. et al. Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD. Neurology. 2003;61:358-364. (Pubitemid 36975966)
43. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC. et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology. 1995;195:65-72.
44. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol. 2007;62:109-119.
45. Soares DP, Law M. Magnetic resonance spectroscopy of the brain:review of metabolites and clinical applications. Clinical Radiology. 2009;64:12-21.
46. Soher BJ, Van Zijl PC, Duyn JH. et al. Quantitative proton MR spectroscopic imaging of the human brain. Magn Reson Med. 1996;35:356-363. (Pubitemid 26072107)
47. Tenforde TS. The Wonders of Magnetism. Bioelectromagnetics. 2003;24:3-11
48. Tong Z, Yamaki T, Harada K, Houkin K. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging. 2004;22:735-742.
49. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592-598.
50. Waldman AD, Rai GS. The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementias proton magnetic resonance spectroscopy study. Neuroradiology. 2003;45:507-512.
51. Wurtman RJBJ, Marie JC. Autocatabolism of choline-containing membrane phopholipids in the pathogenesis of Alzheimer's disease. Neurochem Int. 1985;369-372.
52. Yesavage JA, O'Hara R, Kraemer H, Noda A, Taylor JL. et al. Modeling the prevalence and incidence of Alzheimer's disease and mild cognitive impairment. J Psychiatr Res. 2002;36:281-286.
53. Xuan X, Ding M, Gong X. Proton Magnetic Resonance Spectroscopy Detects a Relative Decrease of N-Acetylaspartate in the Hippocampus of Patients With Dementia With Lewy Bodies. J Neuroimaging. 2008;18:137-141.
54. Zhu X, Schuff N, Kornak J, Soher B, Yaffe K. et al. Effects of Alzheimer's disease on fronto-parietal brain N-acetyl-aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord. 2006;20:77-85.